Executive Summary
Why new products fail after launch: Scale-up manufacturing challenges during development create hidden vulnerabilities that manifest as commercial disappointment after product launch. Product launch failure causes fall into three distinct patterns when companies transition from prototype to commercial production:
Commercial production scaling issues emerge through:
- Technical scale-up compromises where production realities force quality degradation or cost increases that undermine market positioning
- Commercial capability failures where organisations cannot build the support infrastructure necessary to deliver new value propositions to market
- Operational complexity escalation where management capabilities prove inadequate for industrial operations, leading to delivery failures and customer dissatisfaction
These scale-up decisions, made months or years before launch, become root causes of post-launch commercial failure despite technically successful products and proven market demand.
This is the seventh article in our 8-part series on the hidden root causes of product launch failure. Read the previous article on prototyping and testing failures.
Understanding product launch failure causes requires examining how collaborative culture, innovation strategy, value propositions, business models, and prototyping create the foundation for success. Today, we turn to what I consider the most dangerous category of launch failures: products that enter the market successfully but fail commercially due to scale-up manufacturing challenges made during development.
This phase represents the highest financial risk because errors made here prove most expensive – occurring after significant investment in technical development but before the full cost of commercial failure becomes apparent. Commercial production scaling issues often arise where cross-functional collaboration is overlooked, with R&D teams making critical decisions in isolation from operations and commercial leaders.
These failures prove particularly devastating because they occur after significant investment in commercial production, sales team deployment, and market development. Unlike products that never launch due to technical problems, these products appear successful initially but quickly encounter why new products fail after launch – problems that trace back to compromises made during the scale-up phase.
Product Launch Failure Causes: When Scale-Up Decisions Harm Commercial Success
Amyris Biotechnologies exemplifies how scale-up decisions during development can destroy otherwise successful innovations. The company launched their biofuel products commercially with established distribution partnerships and customer contracts. However, scale-up realities made their production process “too expensive and inefficient to scale up into making large quantities of price-competitive biodiesel.” Despite achieving technical success that “exceeded technical and pollution standards,” the products remained “commercially anything but successful.”
The company initially projected producing 40 to 50 million litres of farnesene in 2012, but was forced to abandon these targets due to production scaling challenges. While Amyris successfully launched its biotechnology products, scale-up decisions made during development created cost structures that prevented long-term commercial viability, ultimately forcing the company to pivot away from biofuels to higher-margin cosmetics markets.
BioAmber provides another instructive example. Their fermentation-based bio-succinic acid achieved excellent performance in laboratory settings and successfully launched commercially with multiple customer contracts secured. However, the commercial production facility in Sarnia revealed systematic problems: fermentation yields degraded significantly at commercial scale, downstream purification proved more complex and expensive than laboratory demonstrations suggested, and production costs achieved $2.23/kg versus market requirements of under $1.50/kg. The product entered the market – customers were buying, the technology worked, and market demand existed – but scale-up decisions made during development created cost structures that made long-term commercial success impossible, leading to bankruptcy in 2018 despite $147 million in facility investment.
Three Scale-Up Failure Patterns That Destroy Launched Products
In my work across Agriculture, Food, and Chemicals industries, I’ve identified three distinct patterns where scale-up decisions during development create vulnerabilities that manifest as commercial disappointment after launch.
1. Technical Scale-Up Compromises: When Production Realities Undermine Market Positioning
The first failure pattern occurs when the transition to commercial production forces technical compromises that degrade product performance or increase costs beyond market acceptance levels. These failures often trace back to inadequate collaboration between R&D and operations teams during development.
Operations disconnection creates technical scale-up blindness. When operations directors aren’t informed of product innovations early in the development process, they cannot identify manufacturing challenges that will emerge during scale-up[7]. R&D teams may select processes, materials, or quality parameters that work perfectly in laboratory settings but create insurmountable challenges at commercial scale.
Product quality degradation at commercial scale represents the most common technical compromise. When scaling chemical processes from laboratory to commercial production, companies frequently encounter changes in reaction kinetics, heat transfer efficiency, and mixing patterns that affect final product properties[7]. Quality variations that are negligible in small laboratory batches can become significant at commercial scale due to different surface area-to-volume ratios, residence time distributions, and temperature control challenges[8].
These technical compromises force difficult decisions: accept reduced performance characteristics or invest in expensive process modifications that may not be economically viable. When customers have committed to purchasing based on prototype performance, discovering that the commercial product delivers diminished benefits creates immediate market credibility problems that spread rapidly through industry networks.
Production cost escalation beyond market pricing creates equally devastating commercial failures. Food processing companies developing novel preservation technologies often discover that energy requirements, labour needs, and equipment maintenance costs at commercial scale significantly exceed pilot projections due to heat recovery inefficiencies, equipment scaling challenges, and operational complexity that only manifests at industrial scale[6].
Scale-dependent performance variations destroy products in applications requiring consistent results[8]. Agricultural input companies frequently encounter this challenge when soil treatment products that perform consistently in laboratory greenhouses show significant variation across different field conditions, soil types, and weather patterns at commercial scale.
2. Commercial Capability Scaling Issues: When Organisations Cannot Support New Value Propositions
The second failure pattern occurs when companies successfully scale production but fail to build the commercial capabilities necessary to deliver new value propositions to market. While significant attention and resources are devoted to operations and plant scale-up, commercial capability requirements are often underestimated. When commercial leaders aren’t adequately informed early in development, they lack sufficient time to build technical support teams, distribution partnerships, customer education programs, and application engineering capabilities that require months or years to develop effectively.
Supply chain and value chain complexity overwhelms commercial capabilities. Commercial production requires fundamentally different supply chain management than laboratory operations. At the laboratory scale, companies typically source high-purity materials from specialty suppliers with minimal quality variation. Commercial production requires managing multiple suppliers, qualifying alternative sources, implementing quality systems, and coordinating logistics for raw materials representing a significant portion of total costs[10].
McKinsey research on materials commercialization identifies polycarbonate (PC) automotive glazing as a classic example of value chain complexity failure[6]. Although PC glazing offers dramatic weight-reduction benefits, “it has taken far longer than expected to gain scale.” The challenge lies not in technical performance but in commercial complexity: “Adoption of PC glazing requires multiple supplier tiers to change their production processes, which they are unwilling to do unless they have a clear promise that OEMs will buy the new material. OEMs, however, are unwilling to buy the new material until they see a stable supply chain”[6]. This catch-22 situation demonstrates how novel value propositions requiring coordinated value chain changes can fail despite superior technical performance.
Technical support scaling inadequacy destroys customer confidence. When companies move from commodity products to specialty applications requiring sophisticated technical support, they often underestimate the commercial capabilities needed. Specialty chemical companies launching new value propositions discover that “technical sales teams face a never-ending game of whack-a-mole due to the ever-evolving challenges they must navigate”[9]. The complexity increases when serving multiple market segments simultaneously, as “within a given sales team, there may only be one or two people who understand the intricacies of the industry”[9].
Distribution channel velocity limitations consistently surprise companies during commercial ramp-up. Research across multiple industries shows that distributors face significant constraints in introducing new products: limited promotional resources, shelf space competition, working capital constraints, and sales force bandwidth[6]. Even breakthrough products with excellent customer acceptance during trials may find that distributors cannot support projected commercial volumes due to these structural limitations.
Geographic and market segment expansion amplifies commercial complexity. When companies scale into new geographies or market segments with differentiated value propositions, they discover that commercial capabilities developed for existing markets often prove inadequate. New regions may require different regulatory expertise, local technical support capabilities, and culturally adapted sales approaches that weren’t anticipated during production scale-up planning. Companies may also discover that outside their core markets, current commercial capability and channel structures are simply inadequate, as more developed structures weren’t needed for previous products.
3. Operational Complexity Escalation: When Management Cannot Execute Commercial Operations
The third failure pattern occurs when organisations cannot build the operational capabilities necessary to deliver products consistently at commercial scale, creating customer satisfaction problems that destroy market acceptance. This pattern frequently emerges when operational complexity is underestimated during collaborative development planning.
Multi-shift operational challenges surprise research-focused organisations. Laboratory operations typically run during standard business hours with highly educated staff supervision. Commercial production requires continuous operations with varying skill levels, comprehensive equipment maintenance programs, and safety culture development across diverse workforce populations[6]. Industry research shows that quality variations across different operational periods due to training inconsistencies and process control challenges frequently create customer complaints that can eliminate profitability for extended periods[8].
Avoiding Commercial Production Scaling Issues: Setting the Stage for Launch Success
Companies that make scale-up decisions with commercial success in mind, supported by collaborative cultures that engage operations and commercial leaders early in development, position themselves to avoid the devastating pattern of successful product launches followed by commercial disappointment.
The key insight is recognising that scale-up decisions made during development become constraints that will determine commercial success or failure for years after launch. Technical compromises, production cost structures, and commercial capabilities established during scale-up cannot be easily changed once commercial operations begin. However, organisations with collaborative cultures that engage operations and commercial leaders early in development can anticipate and address these constraints before they become insurmountable barriers[6].
The scale-up phase represents the final opportunity to ensure that development investments create commercial success rather than expensive disappointment. Research shows that the transition from laboratory to manufacturing in microbial bioprocesses typically requires 3-10 years, with high financial risk if process performance deteriorates during scale-up[8]. Companies that approach scale-up systematically—balancing technical feasibility with commercial reality whilst maintaining collaborative cultures that engage all stakeholders early—dramatically increase their chances of achieving sustainable profitability after launch.
Evaluating Your Scale-Up Decision Making
Before moving to our next article on governance failures, consider these critical questions about how your organisation makes scale-up decisions:
- Do your scale-up plans prioritise technical feasibility or commercial success metrics?
- Are operations and commercial leaders involved early enough in development to anticipate scale-up challenges?
- How will production cost structures at commercial scale affect your market positioning and pricing strategy?
- What commercial capabilities will your new value proposition require that don’t exist in your current organisation?
- What timeline and volume assumptions drive your scale-up investments, and how realistic are they?
Your answers will reveal whether your scale-up approach positions your innovations for commercial success—or creates hidden vulnerabilities that will manifest as post-launch disappointment.
What scale-up challenges have you encountered that affected commercial success after launch? Share your experiences in the comments—your insights could help others avoid similar setbacks.
About Arkaro
Arkaro is a B2B consultancy specialising in Strategy, Innovation Process, Product Management, Commercial Excellence & Business Development, and Integrated Business Management. With industry expertise across Agriculture, Food, and Chemicals, Arkaro’s team combines practical business experience with formal consultancy training to deliver impactful solutions.
Our collaborative ‘do it with you’ approach helps organisations identify and address the root causes of scale-up failures before they become commercial disappointments. We work closely with clients to build sustainable capabilities that support successful transitions from prototype to profitable production.
We don’t just coach – we get on the pitch with you
Connect With Us
💬 Ready to strengthen your innovation capabilities? Contact us to discuss how we can help you have more successful product launches.
🔗 Visit us at www.arkaro.com
👥 Follow our updates: Arkaro on LinkedIn
References
[1] Sentience Institute. (2019). What Can Biofuel Commercialization Teach us about Scale, Failure, and Success in Biotechnology? Case study analysis of Amyris, KiOR, REG, and Novozymes. https://www.sentienceinstitute.org/biofuels
[2] MIT Technology Review. (2012, February 10). Amyris Gives Up Making Biofuels: Update. https://www.technologyreview.com/2012/02/10/20483/amyris-gives-up-making-biofuels-update/
[3] Fast Company. (2012, August 8). The Rise And Fall Of The Company That Was Going To Have Us All Using Biofuels. https://www.fastcompany.com/3000040/rise-and-fall-company-was-going-have-us-all-using-biofuels
[4] Seeking Alpha. (2014, June 5). Gevo, An Extremely Overvalued Ethanol Plant, Has Failed With Its Isobutanol Project. https://seekingalpha.com/article/2252503-gevo-an-extremely-overvalued-ethanol-plant-has-failed-with-its-isobutanol-project
[5] BioAmber Inc. Annual Reports and SEC Filings (2014-2018). Production cost analysis and facility performance data.
[6] CRB Group. (2018, July 31). Scaling food production: 12 critical dos and don’ts. https://www.crbgroup.com/insights/scaling-food-production
[7] CRB Group. (2022, March 4). 6 considerations for scaling up an industrial biotechnology process. https://www.crbgroup.com/insights/biotechnology/industrial-biotechnology
[8] Yang, X., & Noorman, H. J. (2021). Scale-up of industrial microbial processes. FEMS Microbiology Letters, 365(13). https://pmc.ncbi.nlm.nih.gov/articles/PMC5995164/
[9] 7 Challenges Facing Technical Sales Teams at Specialty Chemical Companies. HelloNesh. https://www.hellonesh.io/blog/7-challenges-facing-technical-sales-teams-at-specialty-chemical-companies
[10] Estimation of production cost and revenue. Northwestern University Chemical Process Design Open Textbook. https://processdesign.mccormick.northwestern.edu/index.php/Estimation_of_production_cost_and_revenue
